New antibiotic, ketolide: The first of its kind
May 3rd 2004Clinicians will soon be able to offer their patients with upper respiratory infections (URIs) an antibiotic that avoids bacterial resistance by 2 different mechanisms. The FDA recently approved telithromycin (Ketek, Aventis), the first member of the ketolide class of antibiotics to be approved for use in the U.S. Telithromycin is approved for the treatment of acute exacerbation of chronic bronchitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; acute bacterial sinusitis due to S. pneumoniae, M. catarrhalis, or Staphylococcus aureus; and community-acquired pneumonia of mild-to-moderate severity due to S. pneumoniae (including multidrug-resistant isolates), H. influenzae, Chlamydophila pneumoniae, or Mycoplasma pneumoniae. The drug will be available in pharmacies by the end of July.
New antidepressant offers substantial savings
April 19th 2004Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.
Innovative technologies improve patient compliance
April 19th 2004New drug delivery systems such as transdermal patches can keep drugs and biological agents at desirable levels in the body, reducing the need for frequent dosing and improving compliance. Said Robert S. Langer, Ph.D., the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at Massachusetts Institute of Technology in Cambridge, "Because of recent technological innovations, patient compliance is improving tremendously and new treatments are being developed." Such drug delivery systems may benefit those with mental illness. Continuous medication use is absolutely necessary for these patients, because of the "24/7" nature of conditions such as schizophrenia, said Robert R. Conley, MD, a professor of psychiatry and pharmacy science at the University of Maryland School of Medicine in Baltimore. Langer and Conley spoke at an AMA media briefing held recently in New York City. Funding for the conference was provided by an unrestricted educational grant from Janssen..